Trials / Unknown
UnknownNCT00564759
Gene Therapy for Chronic Granulomatous Disease
Phase I/II Gene Therapy Study for X-Linked Chronic Granulomatous Disease
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Johann Wolfgang Goethe University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study is to evaluate the side effects and risks after infusion of retroviral gene corrected autologous CD34+ cells of the peripheral blood of chemotherapy conditioned (busulphan)patients with chronic granulomatous disease (CGD). Also gene corrected and functional active granulocytes in the peripheral blood and the engraftment in the bone marrow of the patients will be monitored an documented.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | retroviral SF71-gp91phox transduced CD34+ cells | autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells |
Timeline
- Start date
- 2004-01-01
- Completion
- 2008-12-01
- First posted
- 2007-11-28
- Last updated
- 2007-11-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00564759. Inclusion in this directory is not an endorsement.